Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cyclacel Reaches Agreement With FDA

By Drug Discovery Trends Editor | September 13, 2010

BERKELEY HEIGHTS, N.J. (AP) – Cyclacel Pharmaceuticals Inc. said it has reached a deal with the Food and Drug Administration on a design for a late-stage study of a potential cancer treatment and plans to begin patient enrollment before the end of 2010.

Shares of Cyclacel surged 31 cents, or nearly 20 percent, to $1.88 in Monday trading. The stock, which traded at a 52-week low of 75 cents last fall, surged to a year-high of $4.08 in January on positive data for its lung cancer drug before steadily sliding downward over the past several months.

The company is developing its sapacitabine oral capsules as a front-line treatment for elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia. The patients are not candidates for chemotherapy.

AML is a cancer of the blood cells that progresses rapidly and if not treated, could be fatal in a few months. Nearly 9,000 deaths are caused by this cancer each year in the United States

The drug candidate is also currently being studied as a potential treatment for myelodysplastic syndromes – in which blood cells don’t mature in bone marrow – and non-small cell lung cancer.

Date: September 13, 2010
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE